Company Overview and News

 
Asia Pacific loans continue slide to five-year low

2017-12-29 reuters
Hong Kong, Dec 29 (TRLPC) - Syndicated lending in Asia Pacific, excluding Japan, hit a five-year low of US$445.31bn in 2017 and was 4.81% lower than US$467.8bn in 2016 as mergers and acquisitions activity slowed and record G3 bond issuance in dollars, euros, and yen curbed loan volume.

 
Asian lending crashes to five-year low

2017-09-29 reuters
HONG KONG, Sept 29 (TRLPC) - Syndicated lending in Asia Pacific, excluding Japan, hit a five-year low of US$292.47bn for the first nine months of 2017, 19.55% lower than the same period last year as more borrowers turned to the bond market and China’s curbs on overseas acquisitions dented volume.

 
China M&A slowdown hurts Asian lending

2017-06-30 reuters
June 30 (LPC/ IFR) - Government measures to control capital outflows from China have taken their toll on outbound M&As as well as related financings, leading to a significant decline in lending in Asia Pacific. Syndicated loan volumes in the region (ex-Japan) tumbled 25% in the first six months of 2017 to US$184.83bn from US$248bn in the same period last year.

 
China Oceanwide seeks more time for U.S. approval of Genworth deal

2017-04-28 reuters
China Oceanwide Holdings Group Co said on Friday it had refiled its application for U.S. approval of its $2.7 billion acquisition of life insurance company Genworth Financial Inc (GNW.N), in a bid to add more time to the regulatory review.

 
Time Inc says not to sell itself, shares plunge

2017-04-28 reuters
Time Inc (TIME.N) said on Friday it would not sell itself but pursue a strategic plan to boost growth, sending its shares tumbling nearly 19 percent.

 
CDH Investments Said to Lead Buyout of China Retailer Belle - Bloomberg

2017-04-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Hong Kong Stocks Climb to One-Month High Amid Mainland Inflows - Bloomberg

2017-01-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Prada found wanting in assessment of forced labour safeguards | Global development | The Guardian

2016-12-08 theguardian
Ralph Lauren and Hugo Boss also perform modestly in study of quality and transparency of efforts by leading fashion firms to protect against forced labour

 
China shares rise in Hong Kong as US jobs data beat estimates

2016-07-11 themalaymailonline
The Hang Seng China Enterprises Index was up 1.9 per cent as of 10:14am, after sliding 2 per cent last week. — Reuters picHONG KONG, July 11 — Chinese stocks traded in Hong Kong rose the most in seven weeks, joining a global rally as data on US jobs signalled the world’s biggest economy is on a stronger footing.

 
A Shift From Momentum To Value In Asia?

2016-06-05 seekingalpha
Looking back at equity market trends in 2015, we see that like much of the world, Asia (ex-Japan) saw momentum factors perform strongly, while valuation underperformed. However, the trend seems to have changed in 2016, with value outperforming and momentum underperforming. If that trend continues, we look for companies that might benefit.

 
China's Belle annual profit down 38 pct as consumer taste changes

2016-05-25 reuters
HONG KONG May 25 China's Belle International Holdings Ltd said annual net profit fell 38 percent as more and more consumers shift to athleisure products and away from traditional fashion footwear and dress shoes.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...